Urothelial Carcinoma trials recruiting in New York

All Urothelial Carcinoma trials nationally

Cities in New York

Recruiting trials in New York

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
  NCT06695845 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• DBC-664 in Adult Patients With Solid Tumors
  NCT07705035 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
  NCT04977453 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
  NCT06293898 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mineola, New York
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · New York: Buffalo, Hempstead, Manhasset, New York
• Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
  NCT06582017 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, Rochester
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: The Bronx